Haemonetics Q1 Adj $1.02 Beats $1.01 Estimate, Sales $336.17M Beat $335.38M Estimate
Portfolio Pulse from Benzinga Newsdesk
Haemonetics (NYSE:HAE) reported Q1 earnings of $1.02 per share, beating the analyst estimate of $1.01. Sales were $336.17 million, surpassing the $335.38 million estimate. Despite a 2.86% decrease in earnings per share from last year, sales increased by 7.98%.
August 08, 2024 | 10:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Haemonetics reported Q1 earnings of $1.02 per share, beating the analyst estimate of $1.01. Sales were $336.17 million, surpassing the $335.38 million estimate. Despite a 2.86% decrease in earnings per share from last year, sales increased by 7.98%.
Haemonetics' Q1 earnings and sales both exceeded analyst expectations, which is generally positive for the stock. The slight decrease in EPS from last year is offset by a significant increase in sales, indicating strong business performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100